Antipsychotic drugs and their side-effects

목차 (Table of Contents)

• 목차
• Contributors = xi
• Series Preface = xiii
• Neuroscience Editorial Advisory Board = xv
• Preface = xvi
• Part Ⅰ : Basic science = 1
• 1 The pharmacology of the phenothiazines, Butyrophrenones, thioxanthines and disphenylbutylpiperidines / B.E. Leonard = 3
• 1.1 Introdcution = 3
• 1.2 Effects of neuroleptics on dopaminergic and other neurotransmitter systems = 5
• 1.3 Heterogeneity of dopaminergic neurons in the mesocortical system = 8
• 1.4 Ineraction of neuroleptics with non-dopaminergic receptors = 11
• 1.5 Action of neuroleptics on different types of neurotransmitter receptor = 12
• 1.6 Structure-activity relationships and pharmacokinetic aspects = 13
• 1.7 Behavioural and pharmacological properties of the neuroleptics = 17
• 1.8 Clinical pharmacology of the neuroleptics = 21
• 1.9 Hormonal changes resulting from neuroleptic treatment = 22
• 1.10 Conclusion = 23
• 2 The pharmacology of cloapine-like atypical anipsychotics / D.M. Coward = 27
• 2.1 Introduction = 27
• 2.2 Neuroleptic-like properties in animal studies = 30
• 2.3 Atypical properties of clozapine = 31
• 2.4 Neurotransmitter interactions of clozapine and related agents = 33
• 2.5 Mechanisms underlying clozapine's atypicality = 35
• 2.6 Conclusions = 41
• 2.7 Summary = 41
• 3 Phamacology and clinical properties of selective dopamine anagonists with focus on substitued benzamides / Jes Gerlach = 45
• 3.1 Introduction = 45
• 3.2 Antagonism of dopamine receptors = 47
• 3.3 Conclusion and future trends = 59
• 4 Pre- and postsynaptic D$$_{1}$$ to D$$_{5}$$ dopamine receptor mechanisms in relation to antipsychotic activity / John L. Waddington = 65
• 4.1 Phamacological characteristics of dopamine receptor subtypes = 66
• 4.2 D$$_{1}$$ receptor antagonists as putative antipsychotic agents = 69
• 4.3 'Selective' D$$_{2}$$ autoreceptor agonists, antagonists and partial agonists as putative antipsychotic agents = 76
• 4.4 Implications for the dopamine hypothesis of schizophrenia = 81
• 5 Predication of antipsychotic activity / Nadia M.J. Rupniak ; Susan D. Iversen = 87
• 5.1 Introduction = 87
• 5.2 Preclinical screens for antipsychotic drugs = 88
• 5.3 Desirable preclinical profile using dopamine antagonist screens = 89
• 5.4 Preclinical profiles of novel agents suggesting antipsychotic activity = 90
• 5.5 Discussion and targets for future research = 94
• 6 Effects of neuroleptics on neuronal and synaptic structure / P.J. Harision = 99
• 6.1 Neuroleptic effects on neurons = 100
• 6.2 Neuroleptic effects on synapses = 104
• 6.3 Neuroleptic effects in human brain = 106
• 6.4 Neuroleptics and gene expression = 108
• 7 Brain imaging and antipsychotic drugs / P.F. Liddle = 111
• 7.1 Introduction = 112
• 7.2 Brain-imaging techniques = 113
• 7.3 Effects of antipsychotic drugs on brain activity = 121
• 7.4 Occupation of neuroreceptors by antipsychotic drugs = 122
• 7.5 Conclusions regarding antipsychotic drug action = 124
• 8 Phamacokinetics of antipsychotic drugs / S.H. Curry = 127
• 8.1 Introduction = 127
• 8.2 Analytical methods = 128
• 8.3 Neuroleptic drug metabolites = 130
• 8.4 Presystemic elimination (first-pass effect) = 131
• 8.5 Enzyme induction = 133
• 8.6 Binding to plasma protein = 133
• 8.7 pH-dependent phenomena = 134
• 8.8 Elimination half-life = 134
• 8.9 U-shaped clinical-chemical relationships = 135
• 8.10 Changeover from oral medication to depot neuroleptics = 138
• 8.11 Prolactin = 139
• 8.12 Therapeutic monitoring = 139
• 8.13 Conclusion = 141
• Part Ⅱ : Clinical issues = 145
• 9 The assessment of antipsychotic medication in clinical trials / S.R. Hirsch = 147
• 9.1 Introduction = 147
• 9.2 Phase I studies = 148
• 9.3 Phase Ⅱ studies = 148
• 9.4 Phase Ⅲ studies = 150
• 9.5 Phase Ⅳ studies = 150
• 9.6 Fixed-versus flexible-dose studies = 150
• 9.7 Patient selection = 151
• 9.8 Statistical aspects = 152
• 9.9 Rating instruments = 153
• 9.10 Clinical designs for specific purposes = 153
• 9.11 Other measures of pharmacological efficacy = 155
• 9.12 Conclusion = 155
• 10 Indications for antipsychotic drugs / R.G. McCreadie = 157
• 10.1 Schizophrenia = 157
• 10.2 Mania = 163
• 10.3 Delusional depression = 163
• 10.4 Functional psychosis = 164
• 10.5 Dementia = 164
• 10.6 Miscellaneous indications = 165
• 11 Acute treatement / J.M. Kane = 169
• 11.1 Introduction = 171
• 11.2 Indications = 171
• 11.3 Choice of drug = 174
• 11.4 Dosage = 176
• 11.5 Antipsychotic drug dosage equivalenices = 176
• 11.6 Strategies for treating non-responsive patients = 177
• 11.7 Clozapine = 178
• 11.8 Conclusions = 180
• 12 Maintenance antipsychotic medication / J.M. Davis ; P.G. Janicak ; A. Singla ; R.P. Sharma = 183
• 12.1 Introduction = 183
• 12.2 Time-course of relapse = 186
• 12.3 Indications for maintenance = 190
• 12.4 Targeted treatment = 191
• 12.5 Dosagew of medication = 193
• 12.6 Choice of medication = 194
• 12.7 Effect of antipsychotic drugs on the course of schizophrenia = 195
• 12.8 Maintenance drugs and psychosocial treatement = 197
• 12.9 Postpsychotic depression = 198
• 12.10 Supersensitivity = 199
• 12.11 Conclusion = 201
• 13 Depot neuroleptics / D.A.W. Johnson = 205
• 13.1 Introduction = 205
• 13.2 Compliance = 207
• 13.3 Delivery service = 208
• 13.4 Risk of side-effects = 209
• 13.5 Conclusions = 211
• 14 The side-effects of antipsychotic drugs. Ⅰ. CNS and neuromuscular effect / T.R.E. Barmes ; J.G. Edwards = 213
• 14.1 Neuropsychiatric effects = 214
• 14.2 Neuromuscular effects = 217
• 14.3 Autonomic effects = 239
• 15 The side-effects of antipsychotic drugs. Ⅱ. Effects on other physiological systems / J.G. Edwards ; T.R.E. Barnes = 249
• 15.1 Endocrime and metabolic disorders = 250
• 15.2 Immunological reactions = 253
• 15.3 Cutaneous reactions = 253
• 15.4 Ophthalmological reactions = 255
• 15.5 Haematological reactions = 256
• 15.6 Cardiac effects = 258
• 15.7 Respiratory reactions = 260
• 15.8 Gastrointestinal reactions = 260
• 15.9 Helpatic reactions = 261
• 15.10 Sexual dysfunction = 262
• 15.11 Effects on the embryo and newborn = 265
• 15.12 Drug interactions = 267
• 15.13 Conclusions = 270
• Index = 277